Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34+ Cell Transplantation for Elderly Atherosclerotic Ischemia
NCT03098771Unknown
- Sponsor
- Qingdao University
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
01
Overview
Randomised, open-label trial of VEGF165-transfected autologous CD34+ cells in arteriosclerosis obliterans and diabetic foot disease (DFD) (2 arms), sponsored by Qingdao University. Primary endpoint: Ankle-Brachial Index at 6 months. Status: unknown.
02
Drugs
VEGF165-transfected autologous CD34+ cells
03
Conditions
arteriosclerosis obliteransdiabetic foot disease (DFD)
Beyond the preview
Go deeper on NCT03098771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098771.